JeanYves Pavee - Abbott Laboratories President
| ABTT34 Stock | BRL 45.75 0.30 0.65% |
President
Mr. JeanYves F. Pavee is Senior Vice President Established Pharmaceuticals Commercial Strategy of the Company. From 2011 to 2013 Divisional Vice President Established Pharmaceuticals EMEA East. From 2008 to 2011 Divisional Vice President Europe South. He was elected Corporationrationrate Officer 2013. since 2015.
| Age | 51 |
| Tenure | 9 years |
| Phone | 224 667 6100 |
| Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joseph Portera | Costco Wholesale | 65 | |
| James Murphy | Costco Wholesale | 70 | |
| Kyle Malady | Verizon Communications | 55 | |
| Roy Chestnutt | Verizon Communications | 53 | |
| Hans Vestberg | Verizon Communications | 58 | |
| Chris Bartlett | Verizon Communications | N/A | |
| Daniel Mead | Verizon Communications | 60 | |
| James Klauer | Costco Wholesale | 55 | |
| Mike Stefanski | Verizon Communications | N/A | |
| Anthony Skiadas | Verizon Communications | 50 | |
| Roger Gurnani | Verizon Communications | 55 | |
| Franz Lazarus | Costco Wholesale | 71 | |
| Craig Silliman | Verizon Communications | 51 | |
| Stephanie Mitchko | Charter Communications | 53 | |
| Gregory Tomb | Zoom Video Communications | 57 | |
| Richard DiGeronimo | Charter Communications | 45 | |
| Brady Connor | Verizon Communications | N/A | |
| Paul Moulton | Costco Wholesale | 66 | |
| Richard Galanti | Costco Wholesale | 67 | |
| Marni Walden | Verizon Communications | 48 | |
| John Bickham | Charter Communications | 69 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Scott, Independent Director | ||
| Christopher Scoggins, Senior Vice President - Rapid Diagnostics | ||
| Roger Bird, Senior Vice President - U.S. Nutrition | ||
| Michael Dale, Senior Vice President - Structural Heart | ||
| Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Heather Mason, Senior Vice President - Abbott Diabetes Care | ||
| James Farrell, Independent Director | ||
| Phebe Novakovic, Independent Director | ||
| JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets | ||
| Roxanne Austin, Independent Director | ||
| Stephen Fussell, Senior Vice President - Human Resources | ||
| Sally Blount, Independent Director | ||
| Daniel Starks, Independent Director | ||
| Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure | ||
| Thomas Frinzi, Senior Vice President - Abbott Medical Optics | ||
| Lisa Earnhardt, Executive Vice President - Medical Devices | ||
| Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America | ||
| Robert Alpern, Independent Director | ||
| Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics | ||
| Glenn Tilton, Independent Director | ||
| Darren McDew, Independent Director | ||
| Richard Ashley, Executive VP of Corporate Devel. | ||
| Michael Rousseau, President - Cardiovascular and Neuromodulation | ||
| Charles Brynelsen, Senior Vice President - Abbott Vascular | ||
| Hubert Allen, Executive Vice President, General Counsel, Secretary | ||
| Charles Foltz, Senior Vice President - Abbott Vascular | ||
| Brian Yoor, Chief Financial Officer, Executive Vice President - Finance | ||
| John Ginascol, Executive Vice President - Core Diagnostics | ||
| Jared Watkin, Senior Vice President - Diabetes Care | ||
| Brian Blaser, Executive VP of Diagnostic Products | ||
| Scott White, Senior Vice President - International Nutrition | ||
| Deepak Nath, Senior Vice President - Abbott Vascular | ||
| Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
| Mary Moreland, Executive Vice President of Human Resources | ||
| Nancy McKinstry, Independent Director | ||
| Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Thomas Freyman, Executive VP of Fin. and Admin. | ||
| Randel Woodgrift, Senior Vice President - CRM | ||
| Michelle Kumbier, Independent Director | ||
| Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation | ||
| John Capek, Executive Vice President - Ventures | ||
| Miles White, Chairman, CEO and Chairman of Executive Committee | ||
| Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| Elaine Leavenworth, VP Officer | ||
| Edward Liddy, Independent Director | ||
| John Stratton, Independent Director | ||
| Joseph Manning, Senior Vice President - Abbott Nutrition International | ||
| Scott Leinenweber, Licensing Relations | ||
| James Young, VP Officer | ||
| William Osborn, Lead Independent Director | ||
| Michael Warmuth, Executive Vice President - Established Pharmaceuticals | ||
| Robert Funck, Chief Financial Officer, Executive Vice President - Finance | ||
| Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America. | ||
| Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics | ||
| Melissa Brotz, VP Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.07 T | |||
| Shares Outstanding | 20.92 B | |||
| Price To Earning | 40.47 X | |||
| Price To Book | 5.41 X | |||
| Price To Sales | 22.38 X | |||
| Revenue | 43.65 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Abbott Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Abbott Laboratories' short interest history, or implied volatility extrapolated from Abbott Laboratories options trading.
Pair Trading with Abbott Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Abbott Stock refer to our How to Trade Abbott Stock guide.Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Abbott Stock analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |